Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Keeping Ahead of Oncology Advances Requires Vigilance

September 11th 2018

Aditya V. Shreenivas, MD, MSCR, says a habit of continuous learning is the ideal way to stay informed about the latest data.

Dr. Shah Compares Toxicity Profiles of Ibrutinib and Acalabrutinib

September 11th 2018

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, compares toxicity profiles of ibrutinib and acalabrutinib.

Dr. Barrientos on Important Considerations for Patients with MCL

September 10th 2018

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses important considerations for patients with mantle cell lymphoma.

Dr. Locke on CAR T-Cell Therapy in NHL

September 10th 2018

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with non–Hodgkin lymphoma (NHL).

Challenges Remain in MPN Diagnosis and Drug Development

September 10th 2018

Andrew T. Kuykendall, MD, discusses the presentation of myeloproliferative neoplasms, novel agents in development, and the overall outlook of these diseases.

Dr. Chavez on Blinatumomab in ALL

September 7th 2018

Julio Chavez, MD, assistant member, Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center, discusses the use of blinatumomab (Blincyto) in patients with acute lymphoblastic leukemia (ALL).

Dr. Komrokji on the Changing Landscape of AML

September 7th 2018

Rami S. Komrokji, MD, principal investigator, MDS Research Consortium, Aplastic Anemia and MDS International Foundation, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses the changing landscape of acute myeloid leukemia (AML).

Baz Highlights Emerging Regimens in Relapsed/Refractory Myeloma

September 7th 2018

Rachid Baz, MD, discusses the ARROW, ELOQUENT-3, and OPTIMISMM studies and highlights others that are demonstrating equally impressive response rates in patients with relapsed/refractory multiple myeloma.

Dr. Pinilla-Ibarz on the Role of Chemotherapy in CLL

September 7th 2018

Javier A. Pinilla-Ibarz, MD, PhD, senior member, Moffitt Cancer Center, discusses the role of chemotherapy in patients with chronic lymphocytic leukemia (CLL).

Frontline Quizartinib Is Tested in AML Subgroup

September 6th 2018

Quizartinib, a small molecule receptor tyrosine kinase inhibitor targeting FLT3, is currently being evaluated in combination with chemotherapy in patients with newly diagnosed FLT3-ITD–positive AML.

Dr. Shah Compares BTK Inhibitors for Mantle Cell Lymphoma

September 6th 2018

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, compares the 2 available BTK inhibitors for patients with mantle cell lymphoma.

Dr. Smith Advises Clinicians on Diagnosing Double-Hit and Triplet-Hit Lymphoma

September 6th 2018

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, advises clinicians on diagnosing double-hit and triple-hit lymphoma in patients with diffuse large B-cell lymphoma.

KRd Regimen Shows Promise in Newly Diagnosed Myeloma

September 6th 2018

Francesca Gay, MD, PhD, discusses the FORTE trial comparing carfilzomib plus lenalidomide and dexamethasone versus carfilzomib plus cyclophosphamide and dexamethasone in newly diagnosed patients with multiple myeloma.

Dr. Locke Discusses Unanswered Questions With CAR T-Cell Therapy

September 5th 2018

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses unanswered questions with chimeric antigen receptor T-cell therapy.

Dr. Sweet Discusses TKI Discontinuation in CML

August 31st 2018

Kendra Sweet, MD, an assistant member in the Department of Malignant Hematology at Moffitt Cancer Center, discusses discontinuation of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia.

Dr. Kuykendall on the Impact of Ruxolitinib in Myeloproliferative Neoplasms

August 31st 2018

Andrew T. Kuykendall, MD, assistant member, Moffitt Cancer Center, discusses the impact of ruxolitinib (Jakafi) in myeloproliferative neoplasms (MPNs).

Dr. Bello on Biomarkers in Follicular Lymphoma

August 31st 2018

Celeste Bello, MD, hematologist/oncologist, Moffitt Cancer Center, discusses investigational biomarkers in follicular lymphoma.

Looking Beyond Overall Survival in Chronic Myeloid Leukemia

August 30th 2018

As investigators continue to look for ways to improve outcomes for the growing number of patients with CML, the primary goal has shifted from improving overall survival to helping patients achieve treatment-free remission.

Dr. Hutchings on Subgroup Analysis of ECHELON-1 in Hodgkin Lymphoma

August 28th 2018

Martin Hutchings, MD, PhD, staff specialist, Department of Hematology, Finsen Centre, National Hospital, Copenhagen University Hospital, discusses a subgroup analysis of the ECHELON-1 study in Hodgkin lymphoma.

FDA Approval Sought for Once-Weekly Carfilzomib Regimen in Myeloma

August 27th 2018

A supplemental new drug application has been submitted to the FDA for a once-weekly dosing option of carfilzomib to use in combination with dexamethasone for patients with relapsed/refractory multiple myeloma.